<DOC>
	<DOCNO>NCT02272504</DOCNO>
	<brief_summary>The objective study evaluate clinical effectiveness biomarkers , alpha-fetoprotein ( AFP ) , Lens culinaris agglutinin-reactive fraction AFP ( AFP-L3 ) , des-gamma-carboxy prothrombin ( DCP ) , surveillance program patient whose hepatocellular carcinoma ( HCC ) development may potentially miss ultrasound ( US ) . This study expect demonstrate addition biomarkers increase detection rate least 10 % .</brief_summary>
	<brief_title>A Protocol Canadian Prospective Study Hepatocellular Carcinoma Surveillance Using Biomarkers</brief_title>
	<detailed_description>This study prospective randomize control trial ( RCT ) compare surveillance hepatocellular carcinoma ultrasound alone versus ultrasound standard biomarkers . The study conduct initially UHN ( TGH TWH ) . One arm undergo surveillance hepatocellular carcinoma use ultrasound ( US ) alone undergo HCC surveillance US plus biomarkers ( BM ) . The biomarkers use AFP , AFP-L3 DCP ) . Subjects undergo surveillance 6 monthly interval minimum 2 year 4 year . The endpoint comparative effectiveness , define sensitivity specificity detection HCC . The comparison sensitivity , specificity , parameter respect tumor characteristic make among US alone , biomarkers alone , combine use US biomarkers . The target population individual liver cirrhosis HCC detectable enrollment study . The factor contribute cause cirrhosis record play role subject eligibility study</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Patient able willing comply study procedure , sign date informed consent obtain . Patients clinical suspicion cirrhosis base investigator 's evaluation cirrhosis confirm one following : ( see definition cirrhosis ) . Etiology cirrhosis consider determine inclusion study . Patients age 18 year old . Hep B Risk Score &gt; 8 ( table 1 ) Table 1 Variable Risk Score Variable Risk Score Male 2 ALT &lt; 15 0 Female 0 ALT 1544 1 Age 3034 0 ALT &gt; 45 2 Age 3539 1 HBeAg+ve 0 Age 4044 2 AntiHBepositive 2 Age 4549 3 HBV DNA &lt; 300 copies/mL 0 Age 5054 4 HBV DNA 3009999 copies/mL 0 Age 5559 5 HBV DNA 104 99,000 copies/mL 3 Age 6065 6 HBV DNA 105 999,999 copies/mL 5 HBV DNA &gt; 106 copies/mL 4 • Patients confirm HCC CT/MRI enrol . Patients previously HCC treat recurrence free 5 year eligible . Patients cancer ( ) Pregnant Women Patients known diagnosis mental incapacitation affect ability consent . Patients likely transplant within 1 year MELD score great 20 . Patients total direct bilirubin &gt; 3x upper limit normal Patients uncontrollable ascites Glomerular Filtration Rate less 60 . Patients ≥ Grade II hepatic encephalopathy Patients treat warfarin ( DCP test value affect warfarin ) Patients contraindication study procedure , product use constituent ( e.g. , renal failure contrast allergy ) . Patients suffer claustrophobia contraindication MRI Patients cirrhosis successfully treat hepatitis C 3 year prior . However , patient study treat hepatitis C may continue study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>HCC</keyword>
	<keyword>AFP</keyword>
	<keyword>AFP-L3</keyword>
	<keyword>DCP</keyword>
	<keyword>Surveillance</keyword>
	<keyword>biomarkers</keyword>
</DOC>